Notícias e Atividades da Syndax Pharmaceuticals
Presença
A Syndax Pharmaceuticals desenvolve e comercializa medicamentos para câncer e outras doenças graves. Seus produtos e programas de pesquisa apoiam hospitais, especialistas em oncologia e pacientes que precisam de tratamentos medicamentosos direcionados.
Visão geral dos produtos e serviços da Syndax Pharmaceuticals:
- Medicamentos oncológicos
- Terapias-alvo
- Medicamentos hematológicos
- Pesquisa clínica
Receita: ~$100 million
Funcionários: 300
Sede: Waltham, Estados Unidos
Syndax Pharmaceuticals é uma das ...
Syndax Pharmaceuticals é uma empresa listada sob o símbolo SNDX (US).
Executivos
Veja o organograma con seus 27 executivos principais
Biografias mais buscadas da Syndax Pharmaceuticals
- Michael Metzger, Director and Chief Executive Officer
- Jennifer Jarrett, Director
- Martin Huber, Director
Criar um alerta
para seguir os movimentos de executivos da Syndax Pharmaceuticals.
Farmacêutica
Syndax Pharmaceuticals possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).
Popular M&A news in Farmacêutica
- Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
- Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
- Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Syndax Pharmaceuticals
- Syndax Announces Participation at Stifel Healthcare Conference | Syndax Pharmaceuticals, Inc.
- Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 | Syndax Pharmaceuticals, Inc.
- Syndax Announces Participation at the Citi 18th Annual BioPharma Conference | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update | Syndax Pharmaceuticals, Inc.
- Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 | Syndax Pharmaceuticals, Inc.
- Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) | Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer | Syndax Pharmaceuticals, Inc.
- View more press releases Close
Redes sociais sobre Syndax Pharmaceuticals
- Syndax Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Syndax Pharmaceuticals na LinkedIn, X (Twitter) e YouTube
